​Pharmacology - Omalizumab

​Pharmacology - Omalizumab
Action of Omalizumab for Increases the magnitude of both the early and late stages while simultaneously lowering the levels of plasma IgE.

Mode of Action 
As a result of its ability to prevent the binding of IgE to mast cells (and eosinophils), this monoclonal antibody is responsible for lowering the release of mediators.

Administered subcutaneously at intervals of two to four weeks.Demands the administration of experts.
When inhaled corticosteroids and long-acting beta 2-agonists are not sufficient to completely manage chronic allergic asthma, this prescription medication is used in clinical settings.

Adverse Effects
Hypersensitivity responses.